| Name | Title | Contact Details |
|---|
Corium International is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DermTech International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BIA Separations is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interface Biologics Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.